|
1
|
Shepard CW, Finelli L and Alter MJ: Global
epidemiology of hepatitis C virus infection. Lancet Infect Dis.
5:558–567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu JY, Shadbolt B, Teoh N, Blunn A, To C,
Rodriguez-Morales I, Chitturi S, Kaye G, Rodrigo K and Farrell G:
Influence of psychiatric diagnosis on treatment uptake and
interferon side effects in patients with hepatitis C. J
Gastroenterol Hepatol. 29:1258–1264. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Teoh NC, Farrell GC and Chan HL:
Individualisation of antiviral therapy for chronic hepatitis C. J
Gastroenterol Hepatol. 25:1206–1216. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Spennati A and Pariante CM: Withdrawing
interferon-α from psychiatric patients: clinical care or
unjustifiable stigma? Psychol Med. 43:1127–1132. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hauser P, Morasco BJ, Linke A, Bjornson D,
Ruimy S, Matthews A, Rifai A, Indest DW and Loftis JM: Antiviral
completion rates and sustained viral response in hepatitis C
patients with and without preexisting major depressive disorder.
Psychosomatics. 50:500–505. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fried MW, Shiffman ML, Reddy KR, Smith C,
Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G,
Dhumeaux D, et al: Peginterferon alfa-2a plus ribavirin for chronic
hepatitis C virus infection. N Engl J Med. 347:975–982. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Manns MP, McHutchison JG, Gordon SC,
Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M
and Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with
interferon alfa-2b plus ribavirin for initial treatment of chronic
hepatitis C: A randomised trial. Lancet. 358:958–965. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Loftis JM and Hauser P: The phenomenology
and treatment of interferon-induced depression. J Affect Disord.
82:175–190. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Asnis GM, de La Garza R II, Miller AH and
Raison CL: Ribavirin may be an important factor in IFN-induced
neuropsychiatric effects. J Clin Psychiatry. 65:581–582. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Asnis GM, de La Garza R, Rego SA,
Henderson MA and Reinus JF: Interferon for hepatitis C patients
with psychiatric disorders. Am J Psychiatry. 161:2332–2334. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huckans M, Fuller B, Wheaton V, Jaehnert
S, Ellis C, Kolessar M, Kriz D, Anderson JR, Berggren K, Olavarria
H, et al: A longitudinal study evaluating the effects of
interferon-alpha therapy on cognitive and psychiatric function in
adults with chronic hepatitis C. J Psychosom Res. 78:184–192. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Masip M, Tuneu L, Pagès N, Torras X,
Gallego A, Guardiola JM, Faus MJ and Mangues MA: Prevalence and
detection of neuropsychiatric adverse effects during hepatitis C
treatment. Int J Clin Pharm. 37:1143–1151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coman HG, HERŢA DC and Nemeş B:
Psychiatric adverse effects of interferon therapy. Clujul Med.
86:318–320. 2013.PubMed/NCBI
|
|
14
|
Von Elm E, Altman DG, Egger M, Pocock SJ,
Gøtzsche PC and Vandenbroucke JP: Iniciativa STROBE: The
strengthening the reporting of observational studies in
epidemiology [STROBE] statement: Guidelines for reporting
observational studies. Gac Sanit. 22:144–150. 2008.(In Spanish).
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alavian SM, Kabir A, Hajarizadeh B,
Nayebpour M, Dorodi T and Baralle FE: Preliminary report of
interferon α2b in combination with ribavirin for 48 weeks for
treatment of iranian patients with chronic hepatitis C: A
quasi-experimental study. Shiraz E Med J. 7:1–8. 2006.
|
|
16
|
Alavian SM, Hajarizadeh B, Hajibeigi B,
Doroudi T, Hamadanizadeh AK and Abar K: Efficacy and safety of
pegylated interferon alfa-2a plus ribavirin for treatment of
chronic hepatitis C and cirrhosis in Iranian. Hepat Mon. 4:53–58.
2004.
|
|
17
|
Alavian SM, Tabatabaei SV, Keshvari M,
Behnava B, Miri SM, Elizee PK and Lankarani KB: Peginterferon
alpha-2a and ribavirin treatment of patients with haemophilia and
hepatitis C virus infection: A single-centre study of 367 cases.
Liver Int. 30:1173–1180. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alavian SM, Abolghasemi H, Miri SM,
Keshvari M, Karimi Elizee P, Behnava B, Tabatabaei SV, Hajibeigi B
and Lankarani KB: Safety and Efficacy of Pegylated Interferon
Alfa-2a for the Treatment of Hepatitis C in Patients with Major
Thalassemia. Iranian J Biood Cancer. 1:129–137. 2009.
|
|
19
|
Alavian SM, Ahmadzad M, Keshvari M,
Behnava B and Hajibeigi B: Efficacy and safety of Interferon-alpha
(Dferon B®and Ribavirin combination therapy in patients
with chronic hepatitis C in Iran. Hep Mon. 6:11–18. 2006.
|
|
20
|
Bafandeh Y, Saberi FM and BAGHERI LK:
Evaluation of combination therapy with interferon and ribavirin in
patients with chronic hepatitis C. A genotype based study. 2007
|
|
21
|
Forootan H, Sharifi A, Mirmomen SH,
Daryani NE, Ghofrani H, Farahvash M, Nasiri M, Talebi M, Ghavidel
A, Vosoghinia H, et al: A multicenter study to evaluate the safety
and efficacy of heber on (interferon alfa-2b) in combination with
ribavirin for the treatment of chronic hepatitis C in iran. Med J
Islam Repub Iran. 19:7–12. 2005.
|
|
22
|
Jabbari H, Bayatian A, Sharifi AH,
Zaer-Rezaee H, Fakharzadeh E, Asadi R, Zamini H, Shahzamani K,
Merat S and Nassiri-Toosi M: Safety and efficacy of locally
manufactured pegylated interferon in hepatitis C patients. Arch
Iran Med. 13:306–312. 2010.PubMed/NCBI
|
|
23
|
Merat S, Sohrabpour AA, Khaleghi S,
Sohrabi MR, Samimi-Rad K, Radmard AR and Malekzadeh R:
Peginterferon alfa-2a and ribavirin in patients with chronic
hepatitis C and inherited bleeding disorders. Hepat Mon. 4:59–64.
2004.
|
|
24
|
Mirmomen S, Ebrahimi Daryani N, Malekzadeh
R, Zali MR, Haghpanah B, Poursamimi P, Hashemi S and Alavian SM:
The efficacy and safety of peginterferon alpha-2a (PEGASYS)
monotherapy in the treatment of chronic hepatitis C infected
subjects with transfusion dependent thalassemia. Hepat Mon.
4:65–70. 2004.
|
|
25
|
Mirmomen S, Ghofrani H, Forootan Pishbuary
H, Ebrahimi Daryani N, Jafar Farahvash M, Sharifian R, Azmodeh F
and Malekzadeh R: Safety and efficacy of interferon alfa for the
treatment of chronic hepatitis C infected subjects with transfusion
dependent thalassemia in Iran. Med J Islam Repub Iran. 17:87–95.
2003.
|
|
26
|
Namazee N, Sali S, Asadi S, Shafiei M,
Behnava B and Alavian SM: Real response to therapy in chronic
hepatitis C virus patients: A study from iran. Hepat Mon.
12:e61512012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nasser Ebrahimi D, Babak H, AliReza S, Ali
Asad H, Mohammad B, Parisa P and Nikbin M: The efficacy and side
effects of therapy with peginterferon alpha-2 a (PEGASYS) combined
with ribavirin in chronic hepatitis C patients: An open label
clinical trial. Hepat Mon. 2004:71–74. 2004.
|
|
28
|
Pouresmaeeli M, Alavian SM, Keshvari M,
Salimi S and Mehrnoush L: Efficacy and tolerability of
peginterferon alpha-2a and peginterferon alpha-2b in Iranian
patients with chronic hepatitis C. Hepat Mon. 15:e307802015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sandoughdaran S, Alavian SM, Sharafi H,
Behnava B, Salimi S, Mehrnoush L, Karimi Elizee P and Keshvari M:
Efficacy of prolonged treatment with pegylated interferon (Peg-IFN)
and ribavirin in thalassemic patients with hepatitis C who relapsed
after previous peg-IFN-based therapy. Hepat Mon. 15:e235642015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zali MR, Shalmani HM, Norouzinia M,
Alizadeh AH, Nowroozi A and Berouz N: Peginterferon Alfa-2a
(Pegasys) and Ribavirin in the treatment of chronic hepatitis C.
Hepat Mon. 4:75–78. 2004.
|
